Neural Noise

Home-based tACS for Alzheimer's disease: RCT evidence

2 min read

  • A randomized controlled trial tested home-based tACS in patients with Alzheimer’s disease.1
  • Home-based tACS is a feasible delivery platform for noninvasive neuromodulation in neurodegenerative disease.1 1

Weekly enrichment (2026-07-20)

  • The trial is reported as “Home-Based Gamma Transcranial Alternating Current Stimulation in Patients With Alzheimer Disease: A Randomized Clinical Trial” in JAMA Network Open (2025; DOI 10.1001/jamanetworkopen.2025.46556), registered as NCT05643326 (“tACS@Home”) and sponsored by ASST degli Spedali Civili di Brescia, Italy.2 3 4
  • The stimulation specifically delivered gamma-band (40 Hz) tACS over the precuneus, targeting the dysregulated gamma oscillations characteristic of Alzheimer disease; the design was double-blind, randomized, and sham-controlled with an open-label extension.2 3
  • The dosing schedule was 5 sessions per week of 60 minutes each for 8 weeks in the double-blind phase, followed by an additional 8 weeks of open-label gamma tACS for all participants and an 8-week follow-up.2 3
  • Sixty consecutive patients with prodromal or mild AD were screened and 50 were randomized 1:1 to gamma or sham tACS; the cohort had a mean (SD) age of 67.3 (7.8) years and was balanced by sex (25 female, 25 male).3
  • Primary endpoints were safety, feasibility, and clinical efficacy; home-based gamma tACS was reported as safe and well-tolerated, with high adherence and low caregiver burden, supporting feasibility of at-home delivery.3 4
  • Significant benefits favoring gamma over sham were seen for the Clinical Dementia Rating Sum of Boxes (marginal mean difference 0.35; 95% CI 0.10–0.61; p = .007) and the Alzheimer Disease Assessment Scale–cognitive subscale (0.93; 95% CI 0.50–1.36; p = .001), plus improvements in activities of daily living (ADCS-ADL) and associative memory.3
  • Secondary/biological measures included EEG gamma-band power (brain entrainment), TMS-indexed cholinergic transmission, plasma AD biomarkers, and MRI connectivity; the treatment was associated with entrained gamma rhythms and enhanced cholinergic transmission.3
  • Cognitive benefits plateaued after a single 8-week course (suggesting ~8 rather than 16 weeks may be the ideal duration), and no significant changes were detected in plasma AD biomarkers (reported as including Aβ42, Aβ40, p-tau, NFL, and GFAP).3 5

Footnotes

  1. https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xRjg4V0ptUTJ5ZG1SYkdNaEFCVXdxM19HcVJPbXVsRExSSzdfYVpBQ1ZPMjhVQVg3UE56T1pWbnUxa1NuWHh1MjY3UWJzaURPbUtZRFJ3b3JxbUVHWmc?oc=5 ↩ ↩2 ↩3

  2. https://doi.org/10.1001/jamanetworkopen.2025.46556 ↩ ↩2 ↩3

  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC12687098/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  4. https://clinicaltrials.gov/study/NCT05643326 ↩ ↩2

  5. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Gamma_%2840_Hz%29_Stimulation_%28non-pharmcological%29_.pdf ↩

Graph View